Role of hepcidin and iron metabolism in the onset of prostate cancer

Zhao,Bin; Li,Ruiqian; Cheng,Gang; Li,Zhiyao; Zhang,Zhiping; Li,Jun; Zhang,Guoying; Bi,Chengwei; Hu,Chen; Yang,Libo; Lei,Yonghong; Wang,Qilin

doi:10.3892/ol.2018.8544

Role of hepcidin and iron metabolism in the onset of prostate cancer

Authors:
- Bin Zhao
- Ruiqian Li
- Gang Cheng
- Zhiyao Li
- Zhiping Zhang
- Jun Li
- Guoying Zhang
- Chengwei Bi
- Chen Hu
- Libo Yang
- Yonghong Lei
- Qilin Wang
View Affiliations

Affiliations: Department of Urologic Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunan 650118, P.R. China, Department of Orthopedic and Trauma Surgery, Yunnan Second People's Hospital, The Fourth Affiliated Hospital of Kunming Medical University, Kunming, Yunan 650021, P.R. China, Department of Ultrasonic Diagnosis, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunan 650118, P.R. China, Department of Radiology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunan 650118, P.R. China
Published online on: April 20, 2018 https://doi.org/10.3892/ol.2018.8544
Pages: 9953-9958

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to understand the roles of hepcidin and iron metabolism in the onset of prostate cancer. The prostate cancer LNCap, PC3 and DU145 cell lines were transfected with small interfering RNA (siRNA) targeting hepcidin to knockdown hepcidin expression in LNCap, PC3 and DU145 cells. The expression levels of hepcidin in prostate cancer and normal prostate RWPE‑1cells were detected by western blot analysis. Exogenous hepcidin was added into the hepcidin‑silenced cell lines. Intracellular iron levels were detected using a fluorescence assay, and the proliferative and migratory capacities of cells were detected using the MTT and wound‑healing assays, respectively. The apoptotic rate was measured using flow cytometry, and changes in the expression of the iron‑export protein ferroportin on the cell membrane were detected by western blot analysis. Hepcidin expression in prostate cancer cells was significantly higher than that of normal prostate cells (P<0.05). Furthermore, the iron levels of hepcidin‑silenced cells (hepcidin‑ve groups) were significantly lower than those in the cells treated with exogenous hepcidin (hepcidin+ve groups) (P<0.05). The proliferative capacity of the hepcidin+ve cells significantly exceeded those of the hepcidin‑ve groups (P<0.05) and increased over time. In the wound‑healing assay, the number of hepcidin+ve cells present within the scratch sites increased compared with hepcidin‑ve cells, indicating a higher migration rate. Additionally, the expression of ferroportin in the hepcidin‑ve groups significantly exceeded that in the hepcidin+ve groups (P<0.05). Hepcidin is involved in the onset of prostate cancer, most likely by reducing ferroportin expression and increasing intracellular iron levels to enhance the proliferation, migration and anti‑apoptotic capacities of cancer cells.

View Figures

View References

1	Ye L, Kynaston HG and Jiang WG: Bone metastasis in prostate cancer: Molecular and cellular mechanisms (Review). Int J Mol Med. 20:103–111. 2007.PubMed/NCBI
2	Moyer VA: U.S. Preventive Services Task Force: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 157:120–134. 2012. View Article : Google Scholar : PubMed/NCBI
3	Msaouel P, Pissimissis N, Halapas A and Koutsilieris M: Mechanisms of bone metastasis in prostate cancer: Clinical implications. Best Pract Res Clin Endocrinol Metab. 22:341–355. 2008. View Article : Google Scholar : PubMed/NCBI
4	Torti SV and Torti FM: Iron and cancer: More ore to be mined. Nat Rev Cancer. 13:342–355. 2013. View Article : Google Scholar : PubMed/NCBI
5	Johnson M, Autzen P, Robson C, Hoedenmaaker R and Hamdy F: Prognostic value of bone morphogenetic protein 6 expression in clinically organ confined prostate cancer. Eur Urol. 35:5121999.
6	Abbaspour N, Hurrell R and Kelishadi R: Review on iron and its importance for human health. J Res Med Sci. 19:164–174. 2014.PubMed/NCBI
7	Chen D and Xu Y: Relation of iron and cervical cancer. World J Cancer Res. 4:1–3. 2014. View Article : Google Scholar
8	Nemeth E and Ganz T: Regulation of iron metabolism by hepcidin. Annu Rev Nutr. 26:323–342. 2006. View Article : Google Scholar : PubMed/NCBI
9	Legendre C and Garcion E: Iron metabolism: A double-edged sword in the resistance of glioblastoma to therapies. Trends Endocrinol Metab. 26:322–331. 2015. View Article : Google Scholar : PubMed/NCBI
10	Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK and Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 113:1271–1276. 2004. View Article : Google Scholar : PubMed/NCBI
11	Lane DJ, Huang ML and Richardson DR: Hepcidin, show some self-control! How the hormone of iron metabolism regulates its own expression. Biochem J. 452:e3–e5. 2013. View Article : Google Scholar : PubMed/NCBI
12	Anderson GJ and Frazer DM: Iron metabolism meets signal transduction. Nat Genet. 38:503–504. 2006. View Article : Google Scholar : PubMed/NCBI
13	Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE and Hamdy FC: Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer. 78:1219–1223. 1998. View Article : Google Scholar : PubMed/NCBI
14	Malyszko J and Mysliwiec M: Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res. 30:15–30. 2007. View Article : Google Scholar : PubMed/NCBI
15	Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, et al: Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr. 127:907–919. 2015. View Article : Google Scholar : PubMed/NCBI
16	Citelli M, Bittencourt LL, Da Silva SV, Pierucci AP and Pedrosa C: Vitamin A modulates the expression of genes involved in iron bioavailability. Biol Trace Elem Res. 149:64–70. 2012. View Article : Google Scholar : PubMed/NCBI
17	Tanno T, Rabel A, Alleyne M, Lee YT, Dahut WL, Gulley JL and Miller JL: Hepcidin, anaemia, and prostate cancer. BJU Int. 107:678–679. 2011. View Article : Google Scholar : PubMed/NCBI
18	Bobinac D, Marić I, Zoricić S, Spanjol J, Dordević G, Mustać E and Fuckar Z: Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Croat Med J. 46:389–396. 2005.PubMed/NCBI
19	Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A and Vaulont S: Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA. 98:8780–8785. 2001. View Article : Google Scholar : PubMed/NCBI
20	Wrighting DM and Andrews NC: Interleukin-6 induces hepcidin expression through STAT3. Blood. 108:3204–3209. 2006. View Article : Google Scholar : PubMed/NCBI
21	Ganz T and Nemeth E: Hepcidin and disorders of iron metabolism. Annu Rev Med. 62:347–360. 2011. View Article : Google Scholar : PubMed/NCBI
22	De Domenico I, Ward DM and Kaplan J: Hepcidin regulation: Ironing out the details. J Clin Invest. 117:1755–1758. 2007. View Article : Google Scholar : PubMed/NCBI
23	Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, Deng Z, Blanchette N, Arvedson T, Miranti CK, et al: Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 75:2254–2263. 2015. View Article : Google Scholar : PubMed/NCBI